177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors

NCT06632873 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

SSTR2 and Integrin αVβ3 Positive Tumors

Interventions

DRUG: 177Lu-TATE-RGD

Sponsor

Peking Union Medical College Hospital